Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc.

1.98
EUR
0.00
(0.00%)
-0.13EPS
325.33MMarket Cap
Mar 01Next Earn

Total Valuation

EUR

As of June 30, 2026, Rocket Pharmaceuticals, Inc. carries a market capitalization of 325.33M, placing it among publicly traded companies globally. Its enterprise value stands at 98.67M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap325.33M
Enterprise Value98.67M

Important Dates

Rocket Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for March 1, 2027.

Earnings Date3/1/2027

Share Statistics

As of June 30, 2026, Rocket Pharmaceuticals, Inc. has 109.54M shares outstanding.

Shares Outstanding109.54M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio1.01
P/TBV Ratio1.22
P/FCF Ratio-2.24
P/OCF Ratio-2.23

Financial Position

As of June 30, 2026, Rocket Pharmaceuticals, Inc. maintains a current ratio of 9.24, meaning it holds 9.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.72, indicating elevated leverage, while an interest coverage ratio of -96.16 demonstrates limited ability to service its debt obligations.

Current Ratio9.24
Quick Ratio9.06
Debt / Equity6.72
Debt / EBITDA-0.14
Interest Coverage-96.16

Financial Efficiency

Over the twelve months ended June 30, 2026, Rocket Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -4.77, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.09, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 226.25, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-4.77
Return on Assets (ROA)-4.09
Employee Count226.25

Taxes

EUR

Over the twelve months ended June 30, 2026, Rocket Pharmaceuticals, Inc. recorded 7.55M in income tax expense. The company reported a pretax loss of -7.55M and -15.10M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax7.55M

Stock Price Statistics

EUR

As of the close on November 17, 2026, Rocket Pharmaceuticals, Inc.'s stock has declined approximately 24.14% over the past 52 weeks. The 50-day moving average sits at 2.35, while the 200-day moving average is 2.93.

52-Week Price Change-24.14%
50-Day Moving Average2.35
200-Day Moving Average2.93

Income Statement

EUR

Over the twelve months ended June 30, 2026, Rocket Pharmaceuticals, Inc. generated - - in revenue and converted that into -15.10M in net income, yielding earnings per share of -0.13. EBITDA reached -159.25M, while operating income came in at -167.96M.

Operating Income-167.96M
Pretax Income-7.55M
Net Income-15.10M
EBITDA-159.25M
EBIT-167.75M
Earnings Per Share (EPS)-0.13

Balance Sheet

EUR

As of June 30, 2026, Rocket Pharmaceuticals, Inc. holds 248.36M in cash and equivalents against 21.71M in total debt, resulting in a net debt position of -196.51M. Total book value stands at 322.84M, with working capital of 226.03M providing operational flexibility.

Cash & Cash Equivalents248.36M
Total Debt21.71M
Net Debt-196.51M
Equity (Book Value)322.84M
Book Value Per Share2.95
Working Capital226.03M

Cash Flow

EUR

Rocket Pharmaceuticals, Inc. produced -149.03M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -111,163.10 in capital expenditures, free cash flow totaled -149.15M - equivalent to -1.33 per share.

Operating Cash Flow-149.03M
Capital Expenditures-111,163.10
Free Cash Flow-149.15M
FCF Per Share-1.33

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -44.64: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.02, meaning Rocket Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-0.02
FCF Yield-44.64

Stock Splits

Rocket Pharmaceuticals, Inc.'s most recent stock split took place on January 5, 2018 with a 4:1 split ratio.

Last Split Date1/5/2018
Split Ratio4:1

Scores

As of June 30, 2026, Rocket Pharmaceuticals, Inc. has an Altman Z-Score of -2.12, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-2.12